Please login to the form below

Not currently logged in
Email:
Password:

checkpoint inhibitor

This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS scores first oesophageal cancer nod for Opdivo in Japan

BMS scores first oesophageal cancer nod for Opdivo in Japan

The approval in oesophageal cancer is particularly important for BMS as it continues to fight for its place in the PD-1/L1 inhibitor class, while Merck &Co’s Keytruda (pembrolizumab) ... Despite being the first checkpoint inhibitor to reach the market

Latest news

More from news
Approximately 4 fully matching, plus 181 partially matching documents found.

Latest Intelligence

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    These compounds could be used to tackle resistance to kinase inhibitor drugs, for example. ... The lead project in that partnership is an inhibitor of CBL-B, an immune checkpoint that is still in preclinical development and will migrate to Bristol-Myers

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    checkpoint inhibitor Imfinzi such as the POSEIDON trial in first-line NSCLC, are key newsflow events this year. ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... t the only oral JAK inhibitor developer with its eye on that

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

  • New hires at Crescendo, Healx and Galecto New hires at Crescendo, Healx and Galecto

    oncology. Prior to Crescendo, Hashimoto (pictured below, right) led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, and held responsibility for multiple.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics